跳至主要内容
临床试验/NCT05060120
NCT05060120Unknown不适用

Biomarker Panel for Early Diagnosis of Ovarian Torsion

Assuta Ashdod Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年9月12日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
20
试验地点
1
主要终点
preoperative biochemical test -BIOMARKER PANEL FOR OVARIAN TORSION

研究概览

简要总结

The overall goal of the project is to find a panel of novel biomarkers for early detection of ovarian torsion.

详细描述

The overall goal of the project is to find a panel of novel biomarkers for early detection of ovarian torsion.

The specifc aims of the current study are:

  1. Screen for changes in blood protein biomarkers concentrations specifc for patients with ovarian torsion. The biomarkers are: D-Dimer (21.7-5,280 ng/ml), FABP4/A-FABP (0.637-155 ng/ml), GM-CSF (0.012-2.98 ng/ml), ICAM-1/CD54 (6.9-1674 ng/ml), IFN-γ (0.058-14.2 ng/ml), IL-1α (0.005-1.27 ng/ml), IL-6 (0.005-1.2 ng/ml), IL-10 (0.005-1.2 ng/ml), IL-17/IL-17A (0.012-3.1 ng/ml), Park7/DJ-1 (0.26- 63.1 ng/ml), TNF-α (0.01-2.4 ng/ml), TSLP (0.003-0.7 ng/ml), VCAM-1/CD106 (7.8-1891 ng/ml) and VEGF (0.008-2.4 ng/ml).
  2. Compare the amount of oxidative stress defense proteins SOD1, Catalase, and Thioredoxin amount in the peritoneal fluid wash between patients with or without confirmed ovarian torsion. To our knowledge, this is the first study that specifically evaluates the expression of oxidation stress defense proteins in ovarian torsion. The results will enable us to decide whether to include oxidation stress biomarkers within the panel.
  3. Study population methodology and techniques

A prospective, 12-24 months study.

20 Patients with confirmed ovarian torsion will be enrolled.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
12 Years 至 50 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • Female patients between 12 and 50 years who were admitted to the gynecological emergency room at Assuta medical center with signs and symptoms suggestive of ovarian torsion
  • Patients that will undergo laparoscopy for the diagnosis of ovarian torsion
  • Able to provide informed consent for themselves or have a legal guardian that can provide informed consent (in cases of patients under 18 years old)
  • Exclusion criteria:
  • * Patients that are unable to provide informed consent

排除标准

  • 未提供

结局指标

主要结局

preoperative biochemical test -BIOMARKER PANEL FOR OVARIAN TORSION

时间窗: 2 years

Screen for elevation in blood protein biomarkers concentrations specifc for patients with ovarian torsion. The biomarkers are: D-Dimer (21.7-5,280 ng/ml), FABP4/A-FABP (0.637-155 ng/ml), GM-CSF (0.012-2.98 ng/ml), ICAM-1/CD54 (6.9-1674 ng/ml), IFN-γ (0.058-14.2 ng/ml), IL-1α (0.005-1.27 ng/ml), IL-6 (0.005-1.2 ng/ml), IL-10 (0.005-1.2 ng/ml), IL-17/IL-17A (0.012-3.1 ng/ml), Park7/DJ-1 (0.26- 63.1 ng/ml), TNF-α (0.01-2.4 ng/ml), TSLP (0.003-0.7 ng/ml), VCAM-1/CD106 (7.8-1891 ng/ml) and VEGF (0.008-2.4 ng/ml).

次要结局

未报告次要终点

研究者

发起方
Assuta Ashdod Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Oshri Barell

head of gynecology unit

Assuta Ashdod Hospital

研究点 (1)

Loading locations...

相似试验

Biomarker Panel in Ovarian Torsion | 临床试验